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Summary.-Combination chemotherapy with cytosine arabinoside, cyclophospha-
mide and L-asparaginase (Asnase) was given to 22 children with acute lymphocytic
leukaemia (ALL) with a white-cell count greater than 30 x 109/1, and other features
suggestive of poor prognosis. Complete remission was induced in all patients-in 19
after 2 courses of chemotherapy and in the remainder after a third course. During
induction, neutropenia occurred in 18 and severe infection in 3. Anaphylaxis to
Asnase occurred in 8 patients after the second course and one other had transient
Asnase-induced diabetes. All patients received central-nervous-system prophylaxis
after achieving remission, during which they were also treated with weekly vincris-
tine and a 2-week course of prednisolone. Continuation therapy consisted of short
cycles of intermittent chemotherapy and BCG inoculation or long cycles of inter-
mittent chemotherapy± BCG. Life-table analysis shows 46% complete remission
rate at 28 months, with 6 patients all in complete remission followed up between
28 and 41 months. There were minimal complications of continuation therapy, and
BCG inoculation was well tolerated.
IN childhood acute lymphocytic leu-
kaemia (ALL) certain findings at the
time of diagnosis indicate a reduced
likelihood of a good response to standard
treatment. These findings include: age of
less than 2 or more than 12 years, a
white-cell count > 20 x 109/1, marked
infiltration of liver, spleen and lymph
nodes, mediastinal enlargement, and high
numbers of peripheral-blood lympho-
cytes forming rosettes with sheep red
cells at 4°C ("T4") or rosette formation by
marrow lymphoblasts at 37°C (Aur et al.,
1971; Haghbin et al., 1974; Hardisty &
Till, 1968; Henderson, 1969; Jose et al.,
1976; Sen & Borella, 1975; Zippin et al.,
1971).
We have previously reported that
combination chemotherpay with cyto-
sine arabinoside (Ara-C), cyclophospha-
mide (Cy) and E. coli L-asparaginase
(Asnase) induced remission in children who
failed to respond to standard induction
programmes (Lay et al., 1975). Most of
these children had high white-cell counts
at diagnosis. In this paper, we report the
results of treatment from diagnosis of
22 children with a high white-cell count
using the above drugs for induction of
remission, and as continuation therapy,
intermittent chemotherapy with or with-
out BCG.
PATIENTS AND METHODS
All children with ALL whose white-cell
counts at the time of diagnosis were >
30 x 109/1 were entered into the study.
Children with marked lymph-node infiltra-
tion, including the mediastinum, and who
also had marrow infiltration of > 25%
lymphoblasts were included. The relevant
clinical features and laboratory investigations
of the 22 children are shown in Table I.
Their ages ranged from 1 to 14 years, with 4
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children 2 years or less. There were 15 males
and 7 females (X2 = 2-9, 0-1 > P > 0105).
Six children had mediastinal masses at
presentation. White-cell counts were per-
formed by standard automated techniques.
Minor infections were considered to be
present if the child had a temperature of
37-5-38 5°C, no positive bacterial cultures
and returned to normal activity within
10 days.
Remission induction.-All patients started
on allopurinol 10 mg/kg daily orally and
i.v. 5% dextrose-saline 3 l/m2/day with
added bicarbonate 24 h before remission
induction was begun. Induction therapy
consisted ofAra-C 40 mg/M2 andCy40 mg/M2
given by i.v. push 8-hourly for a total of
12 doses, followed by Asnase 30,000u/M2
given daily byi.v. push for 4 days. The second
course of treatment was given 14 days after
completion of the first, or as soon as the
neutrophil polymorphonuclear count had
returned to 109/1. The presence of remission
was monitored by marrow aspiration 7-10
days after the end of 2 or 3 courses of chemo-
therapy. "CNS prophylaxis", using cranial
irradiation (2400 rad) and 4 injections of
intrathecal methotrexate 12 mg/M2 at weekly
intervals, was begun as soon as complete
remissionwasidentified. DuringCNS prophyl-
axis the patients received 4 weekly injections
of vincristine (2 mg/M2) and 2 weeks of
prednisolone (50 mg/m2/day) orally.
Continuation therapy.-One week after
completion of this treatment, usually 9-10
weeks from diagnosis, marrow aspiration was
repeated and if the patient was in remission,
continuation therapy was begun. For 7 of
the children in this study, this consisted
ofshort cycles of a single dose ofCy (200-250
Ing/m2) orally on Da) 1, 6-mercaptopurine
(75 mg/M2) orally on Days 2-23 and metho-
trexate (30 mg/M2) orally on Days 1, 8 and 15.
BCG was administered on Day 29 and the
cycle restarted on Day 36. For the remainder
of the children, long courses of inuermittent
chemotherapy were administered consisting
of vincristine (1-5 mg/M2) on Days 0 and 28,
6-mercaptopurine (75 mg/M2) orally on Days
1-43 and methotrexate (30 mg/mi2) on Days
1, 8, 15, 22, 29 and 36. Chemotherapy was
discontinued from Days 42-56 and, for those
randomized to receive BCG, it was given on
Day 49. The BCG was a lyophilized prepara-
tion of a Pasteur strain (Commonwealth
Serum Laboratories, Melbourne) with a
protein concentration of 75 mg/ampoule and
a viable bacterial count of 6-20 x 106
organisms/mg semi-dry weight. It was ad-
ministered in a total dose as near to 0-25 ml
as possible using a Heaf gun and 4 x 20
punctures.
Total remission was defined as the absence
of symptoms and signs of the disease, the
ability to carry on normal activity, normal
peripheral-blood picture (taking into account
the effects of chemotherapy) and a marrow
aspiration which showed no recognizable
leukaemic blast cells and a total blast-cell
count of < 5%.
RESULTS
Remission induction
Complete marrow remission wasinduced
in all children-in 19 after the second
course of chemotherapy and in 3 after a
third. Complications encountered during
induction therapy were as follows. Neutro-
penia (neutrophil count < 0-5 x 109/1)
occurred in 22 after the first course of
chemotherapy. In 12 of these, the neutro-
phil count returned to 109/1 within 7
days, in 7 within 8-14 days and in 3
within 15-25 days. In 3 patients with
neutropenia there was septicaemia, with
Staphylococcus aureus in 1 and E. coli in
the other 2. Eight other children with
neutropenia had minor infections. Post-
ponement of the second course of chemo-
therapy owing to neutropenia was con-
sidered necessary in 4 patients, the 2
with the E. coli septicaemia and 2 others
without documented infection. Bleeding
during or after the first course of chemo-
therapy occurred in the 2 patients with
septicaemia, and responded to platelet
transfusion. There was no oliguria or
rise in blood urea during or after the
chemotherapy. Six children had anaemia
requiring transfusion after the first course
of chemotherapy, and one was transfused
twice. Although the neutrophil count fell
below 0 5 x 109/1 in 13 patients after the
second course ofchemotherapy, there were
only 3 minor infections.
The major complication of Asnase was
the occurrence ofanaphylaxis in 8 patients
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TABLE I.-Clinicalfeatures and laboratory investigations
Sex
(R) M
F
(R) M
F
(R) M
M
(R) F
M
M
F
(R) F
(R) F
M
M
M
M
(R)M
(R)M
(R)M
M
(R)M
F
(R) - Relapse.
Age
(years)
64
5
3
54
3
91
3
14
94
6 I
41
94
2
2
131
3
31
i1
44
124
1 '4
11
Total white-cell
count (109/1)
141-0
79-0
45-5
42-6
308-0
62-0
36-6
264-0
206-8
80-8
31-5
367 -0
33-6
100-0
162 -0
85-8
77 -6
34-2
149-0
230-0
100-8
60-0
Mediastinal Remission Survival
mass (months) (months)
+
+
+
+
+
8
41+
12
10o
4
30+
14
6±
5±
11+
10
2
37±
34±
13+
38±
4
7
No relapse
25
24±
6
38±
18
45+
17
12+
14
32+
22
8+
7+
12+
24
6
39+
36+
14+
39+
8
8
Measles
30+
26+
19+
39+
during the second course of therapy. All
but one of these tolerated Erwinia
asparaginase. One patient developed tran-
sient diabetes mellitus during the first
course of Asnase and tolerated a reduced
dose of Asnase (6000 u/M2) in the second
course without anycomplications. Fibrino-
gen and blood-ammonia levels were only
determined if there were clinical
indications such as liver dysfunction or
septicaemia. In the patients with septi-
caemia, the fibrinogen level was normal
and blood ammonia was not elevated.
All patients tolerated the CNS pro-
phylaxis and treatment with vincristine
and prednisolone. Irradiation-induced
headache, nausea and drowsiness were
the only complications of CNS pro-
phylaxis.
Remission maintenance
The duration of total remission and
survival of all patients is shown in
Table I. The actuarial duration of total
remission is shown in the Figure. Also
shown is the acturial complete remission
rate of 46 consecutively admitted children
with ALL and white-cell count <
1-0
.9
8
7
0
0
0
0-
.3
.2
.1
46
22
: ....
a.. . 10
- ................... 6
..........
6
2 6 10 14 18
Months Remission
22 26 30
FiG.-Duration of complete remission in 46
patients with a white-cell count < 30 x
109/1 ( ) and the study group
(- ). The figure 10 indicates that 10
patients have been followed from 28 to 50
months; 3 of these have relapsed. The
figure 6 indicates that 6 patients have
been followed from 28 to 41 months; none
of these have relapsed.
30 x 109/1. These children were induced
with vincristine and prednisolone and
given the same CNS prophylaxis as the
study group. Maintenance therapy con-
sisted of short courses of intermittent
chemotherapy with BCG in 21 and long
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TABLE II.-Summary of resultsfrom published treatments of childhood ALL
Author
Haghbin et al.
(1974)
Jacquillat et al.
(1973)
Mathe et al.
(1975)
Sallan et al.
(1978)
Ekert et al.
White-cell
count at
diagnosis
(109/1)
>25
>35
>10
>25
>30
Estimated actuarial
remission rate
50% at 28 months
30% at 24-36 months
20% at 32 months
6/38 relapses* median
follow-up 26 months
46% at 28 months
Number of patients
followed beyond
32 months
1
4
5
* No actuarial results reported.
Significant
difference in
remission rate
comnpared with
patients with
"low" white-cell
count
+ at 14 months
-from 18 months
courses in 25. Although the relapse rate
during the first 14 months in the study
group is significantly greater, as calculated
by the logrank significance test (X2
5 03, 0 05 > P > 0 02), there are no
significant differences in the complete
remission rates at 18 months or later.
There were mainly minor complica-
tions during continuation therapy, but
one child developed measles giant-cell
pneumonia and died in remission. There
were 4 cases of infection (2 of pneumonia,
2 of pyrexia of unknown origin) requiring
hospital admission, and chemotherapy was
postponed on 5 occasions because of
neutropenia. One patient required trans-
fusion for anaemia during continuation
therapy.
BCG inoculation was used in the treat-
ment of 15 patients. Local irritation at
the site of BCG inoculation was the only
complication of its use.
DISCUSSION
Remission was induced with 2-3 courses
of combination chemotherapy in all child-
ren with ALL with features suggest-
ing a poor response to standard treat
ment. Haghbin et al. (1974), using the
"L2" protocol, achieved remission in all
22 patients with white-cell counts >
25 x 109/1, and similar high induction
rates have been reported (Aur et al., 1971)
for other regimens using more than 2
drugs. We have calculated that if the
"true" remission rate were 85%, the
probability ofobserving a 100% remission
rate in 22 patients is 3%.
Our results show that in patients with
white-cell counts > 30 x 109/1, there is
an increased relapse rate during the first
14 months oftreatment, but this difference
disappears from 18 months onward. Sallan
et al. (1978), using intermittent combina-
tion chemotherapy including adriamycin,
have reported similar results (Table II).
Previous reports on the treatment of
high-white-cell-count ALL have shown a
significant difference in remission rates
in patients with high and low white-cell
counts (Table II).
A comparison of the white-cell counts
and the presence or absence of a mediasti-
nal mass in patients who relapsed and
those who remained in remission showed
no significant difference (Table I). Un-
fortunately, leukaemia cell-membrane
markers were not obtained on the marrow
specimens ofthe majority ofthose patients
and we are therefore unable to determine
whether the early relapses occurred in
patients with T-cell leukaemia.
Recent experimental evidence suggests
that the combination ofAra-C followed by
Asnase is synergistic in the L5178Y
murine leukaemia (Schwartz et al., 1977).
It may be that the particular effective-
ness of the induction regimen is related
to the sequential use of these drugs. The
622CHILDHOOD ALL WITH HIGH WHITE-CELL COUNTS 623
addition of an alkylating agent, Cy, to
this combination may facilitate destruc-
tion of cells in GI, GO or extended GI
phase of the cell cycle.
The use of intermittent chemotherapy
during maintenance has been well tolera-
ted by the patients. Those patients treated
with the "short" cycles of chemotherapy
had only 3/5 of the dose of a similar
programme given continuously. Those
patients treated with "long" cycles had
3/4 of the dose of the same programme
given continuously. Both groups had far
less intensive chemotherapy than that
used by Sallan et al. (1978), who have
reported similar results. This suggests
that, either intensive chemotherapy may
be unnecessary to maintain an adequately
induced remission, or BCG inoculation
may be exerting an anti-leukaemia effect
in these patients. This can only be answer-
ed by appropriately randomized studies,
and such as is in progress in our labora-
tory.
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